Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with
substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the …

Despite the development of pharmacological therapies that are effective in slowing the
progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal …

Background: In the past two decades, many advances have been made to our
understanding of interstitial lung disease (ILD) and the way we approach its treatment …

Idiopathic pulmonary fibrosis (IPF) is an advancing and fatal lung disease with increasing
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …

Background Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …

Lung transplantation has evolved into a life-saving treatment with improved quality of life for
patients with end-stage respiratory failure unresponsive to other medical or surgical …

Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology,
primarily affects older adults and leads to a progressive decline in lung function and quality …

Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung
disease. The combination of poor prognosis, uncertainty of disease course and severe …

Background Although depression and anxiety represent significant yet treatable
comorbidities in patients with idiopathic pulmonary fibrosis (IPF), their impact on the clinical …